# Clinical dietitian-led nutrition counseling and exercise to reduce cardiovascular risk in adults living with a BMI above 27 and severe mental illness: the NORMI-Heart trial protocol

**Authors:** Madeleine Elisabeth Angelsen, Hemen Najar, Mette Svendsen, Magne Thoresen, Dawn Elizabeth Peleikis, Kjetil Retterstøl

PMC · DOI: 10.3389/fnut.2026.1700251 · Frontiers in Nutrition · 2026-02-12

## TL;DR

This study tests if dietitian-led nutrition counseling and exercise can reduce heart disease risk in people with severe mental illness and high BMI.

## Contribution

The study introduces a novel lifestyle intervention combining clinical dietitian counseling and structured exercise for individuals with severe mental illness.

## Key findings

- The trial will assess the efficacy of a 6-month lifestyle program on cardiovascular risk in adults with severe mental illness.
- Results may support integrating clinical dietitians into mental health care to improve cardiometabolic outcomes.
- The study will evaluate the feasibility and real-world applicability of the intervention in psychiatric care settings.

## Abstract

Severe mental illness (SMI) is associated with high cardiovascular disease (CVD) risk. Important contributors are poor diet quality, physical inactivity, and metabolic side effects of antipsychotic medication entailing significant weight gain. Evidence implies that dietary counseling delivered by clinical dietitians leads to greater improvements in diet quality, weight management, and cardiometabolic health than counseling delivered by non-specialist health personnel, especially when combined with increased physical activity. However, randomized controlled trials (RCTs) testing clinical dietitian-led nutrition counseling integrated with structured exercise across diverse treatment modalities in psychiatric care remain scarce.

The Norwegian Mental Illness Heart Health (NORMI-Heart) study will evaluate the efficacy and applicability of a 6-month lifestyle program, combining individualized, clinical dietitian-led nutrition counseling focused on weight reduction and improved dietary quality, and moderate-to-vigorous exercise training, on CVD risk in adults with SMI in Oslo, Norway.

This parallel-group RCT will recruit 70 overweight adults with SMI. Participants will be randomized to a 6-month diet and lifestyle intervention, or control. The intervention is individualized and includes monthly one-to-one sessions with a clinical dietitian focusing on heart-healthy eating and weight reduction, monthly supervised group exercise, and support to follow an individual exercise program. Control participants will receive treatment as usual (TAU). The NORMI-Heart Trial aims to evaluate the effect of the intervention on estimated CVD risk.

This trial aims to provide evidence on the effectiveness, feasibility, and real-world applicability of clinical dietitian-led nutrition counseling combined with structured exercise for reducing CVD risk in individuals with SMI. Findings may strengthen the scientific and policy rationale for integrating clinical dietitians as a standard part of multidisciplinary mental health care. Results will also inform scalable, integrated lifestyle care models in mental health services.

ClinicalTrials.gov Identifier: [NCT07085923].

## Linked entities

- **Diseases:** cardiovascular disease (MONDO:0004995)

## Full-text entities

- **Genes:** MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, NEFL (neurofilament light chain) [NCBI Gene 4747] {aka CMT1F, CMT2E, CMTDIG, NF-L, NF68, NFL}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}, APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, LPA (lipoprotein(a)) [NCBI Gene 4018] {aka AK38, APOA, LP}, APOA1 (apolipoprotein A1) [NCBI Gene 335] {aka AMYLD3, HPALP2, apo(a)}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}
- **Diseases:** metabolic dysregulation (MESH:D021081), schizotypal (MESH:D012569), obesity (MESH:D009765), weight gain (MESH:D015430), overweight (MESH:D050177), stroke (MESH:D020521), fatigue (MESH:D005221), Diabetes (MESH:D003920), neurocognitive decline (MESH:D060825), Alzheimer's disease (MESH:D000544), substance abuse (MESH:D019966), Mental Illness (MESH:D001523), Schizophrenia (MESH:D012559), anxiety (MESH:D001007), metabolic syndrome (MESH:D024821), inflammation (MESH:D007249), sleep disturbance (MESH:D012893), pain (MESH:D010146), delusional (MESH:D012563), SMI (MESH:D045169), cognitive decline (MESH:D003072), FACT (MESH:D003147), depression (MESH:D003866), social anxiety (MESH:D000072861), Dementia (MESH:D003704), bipolar I and II disorders (MESH:D001714), schizoaffective (MESH:D011618), heart attack (MESH:D009203), -organic psychotic disorders (MESH:D019965), CVD (MESH:D002318), weight (MESH:D015431), bipolar affective disorder (MESH:C564108)
- **Chemicals:** NE (MESH:D009356), biotin (MESH:D001710), Cholesterol (MESH:D002784), lithium (MESH:D008094), Omega-3 (MESH:D015525), C (MESH:D002244), triglycerides (MESH:D014280), fat (MESH:D005223), sugar (MESH:D000073893), alcohol (MESH:D000438), vitamin B6 (MESH:D025101), DHA (MESH:C027493), folate (MESH:D005492), glucose (MESH:D005947), pantothenic acid (MESH:D010205), vitamin B12 (MESH:D014805), lipid (MESH:D008055), thiamine (MESH:D013831), homocysteine (MESH:D006710), niacin (MESH:D009525), carbohydrate (MESH:D002241), Lp(a) (MESH:D010649), riboflavin (MESH:D012256), GBO (-), T4 (MESH:D013974), caffeine (MESH:D002110), 25-hydroxyvitamin D (MESH:C104450)
- **Species:** Nicotiana tabacum (American tobacco, species) [taxon 4097], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12935603/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12935603/full.md

## References

54 references — full list in the complete paper: https://tomesphere.com/paper/PMC12935603/full.md

---
Source: https://tomesphere.com/paper/PMC12935603